Legend Biotech Corporation specializes in the development of advanced cellular therapies, primarily utilizing chimeric antigen receptor T-cell (CAR-T) technology to treat hematologic malignancies and solid tumors. The company transitioned from a clinical-stage entity to a commercial organization following the regulatory approvals of its flagship product, CARVYKTI (ciltacabtagene autoleucel), which is co-developed and globally commercialized in partnership with Johnson & Johnson. Beyond multiple myeloma, Legend Biotech is advancing a robust pipeline of autologous and allogeneic cell therapy candidates targeting various cancers. Originally founded as a subsidiary of GenScript Biotech Corporation, the company maintains a significant global footprint with operations spanning the United States, Europe, and Asia to support its specialized manufacturing and clinical development needs.
